Abbott announced that the FDA has approved an infant-specific dose of Creon (pancrelipase delayed-release capsules) to treat exocrine pancreatic insufficiency due to cystic fibrosis. The new dosage strength will provide 3000 lipase units, 9500 protease units, and 15000 amylase units.

Creon 3000 is expected to be available mid-August 2011.

For more information call (800) 633-9110 or visit